Two Mid-Cap Life Insurance Stocks That Could Double in Two Years

Kyle is a member of The Motley Fool Blog Network -- entries represent the personal opinion of the blogger and are not formally edited.

The life insurance industry has been facing a tough combination of extreme pressure on product pricing as well as low interest rates. This industry pressure has been exasperating insurers over the past few years and weighing on stock prices.

Today, the market provides two compelling opportunities to purchase robust life & health insurers at less than half of their equity book value. At currently reduced prices, both recapitalized businesses with improving return on asset metrics could reasonably double in valuation over the next few years.

<img src="/media/images/user_15200/mid-cap-life-insurers-table_1_large.jpg" />

CNO Financial

CNO Financial ) is a life, health, and long term care insurance business focusing on middle class and retired Americans. CNO recently invigorated their recapitalization by issuing low cost long term debt and paying back shorter term debt and convertible shares while reducing outstanding shares by 12%.

CNO is currently trading at 0.43x book value. Given the aforementioned industry issues, CNO Financial’s return on equity (“ROE”) was 3.9% for the 12 month period ending 9/30/12. Yet the product pricing environment continues to improve and a return to high single digit ROE metrics is reasonable over the next few years.

CNO Financial Business Units

Banker’s Life & Casualty sells life insurance, long term care, annuities, Medicare Supplement / Part D / Advantage plans to middle income Boomers and retirees. Banker’s Life is easily the largest division of CNO worth 2/3rds of CNO’s value.

Banker’s Life has been recently shifting away from annuity sales. Third quarter total sales declined 5% from the second quarter, reflecting an annuity sales decline of 35% while life insurance sales rose 5%, medical supplemental insurance rose 9%, and short term care sales rose 8%. Banker’s Life is targeting a 14% IRR for its expanding long term care segment.

Like Banker’s Life, Washington National sells a similar suite of products to working Americans. Washing National’s core segment sales were up 9% in the third quarter. CNO’s third segment, Colonial Penn, sells simple, low cost life insurance to lower & middle income retirees in urban/metro areas.


At 9/30/12, CNO had $310 million of liquidity including $150 million of deployable capital at the holding company. Segment EBIT grew from $309.4 million in 2010 to $344.3 million in 2011 and is on pace through 9/30/12 to deliver north of $375 million in 2012.

CNO has $893 million of net operating loss carry-forwards which are worth roughly $610 million when discounted over forward years at 10%.


With a recapitalized balance sheet and improving cash flow and ROE metrics, CNO Financial’s stock price has the potential to dramatically increase in the coming years. CNO generated $250 million during the first 9 months of 2012 and could be producing $400 to $500 in free cash annually over the next few years.

In 2015, management believes they can be an investment grade company producing 9% ROE paying 20% of earnings as a dividend. If this happens, CNO could easily trade for book value which would imply a value of $25 per share which would represent a 150% gain from today’s stock price.


Genworth Financial )

Like CNO Financial, Genworth’s main economic unit is its US life & health business. However, Genworth also owns a mortgage insurance business in the US, Canada, and Australia as well as a US wealth management business and an international protection insurance arm.

As you may expect, Genworth’s balance sheet was significantly impaired by losses in the US mortgage insurance business over the past 5 years. This affected Genworth’s debt ratings and reduced the equity price as liquidity concerns arose. Yet, in late October, the company’s board implemented a strategy which will provide the company ample liquidity to operate over the next couple years until the mortgage insurance business returns to profitability.

Genworth recently announced their intentions of divesting the non-core businesses of (1) international protection and (2) wealth management. This announcement follows the January 2011 exit of the variable annuity business and the October 2011 exit from selling supplemental Medicare insurance products.

Upon completion of these divestitures, Genworth will have two main business lines (1) U.S. life & long term care insurance and (2) global mortgage insurance with the majority of business in the US, Canada, and Australia. (Note: Genworth is planning to partially IPO the Australian mortgage insurance business in late 2013.)


Let’s assume the International Insurance segment sells for $450 million (70% of book value) and the US Wealth Management segment sells for $300 million (70% of book value). This $750 million plus the roughly $1 billion Genworth currently has on the balance sheet would place the insurer in an enviable balance sheet position.

Remaining Segment Valuation

<img src="/media/images/user_15200/gnw-remaining-segment-valuation_large.jpg" />


Under the aforementioned conservative scenario, Genworth would be worth $11 billion dollars which represents only 68% of book value and 1.16x tangible book value. Adding back cash and removing debt to calculate share price, at this reasonable valuation Genworth shares would trade at $16.00 and represent a double from today’s offering.

Compared to CNO, Genworth is unlikely to trade at equity book value over the next few years due to the extreme historical losses from the mortgage insurance business. However, given Genworth’s initial price of 0.22x book value, the stock could double and still not trade at book value.

GrizzlyRock is long Genworth Financial. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. Is this post wrong? Click here. Think you can do better? Join us and write your own!

blog comments powered by Disqus